Skip to main content

DiaMedica Therapeutics announces $30M private placement to continue clinical development

The Plymouth-based company will use the proceeds to continue its clinical and product development for DM199, including a recently initiated trial.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.